Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Antiviral agents blocking SARS-CoV-2 viral replication are desperately needed to complement vaccination to end the COVID-19 pandemic. Viral replication and assembly are entirely dependent on two viral cysteine proteases: 3C-like protease (3CLpro) and the papain-like protease (PLpro). PLpro also has deubiquitinase (DUB) activity, removing ubiquitin (Ub) and Ub-like modifications from host proteins, disrupting the host immune response. 3CLpro is inhibited by many known cysteine protease inhibitors, whereas PLpro is a relatively unusual cysteine protease, being resistant to blockade by such inhibitors. A high-throughput screen of biased and unbiased libraries gave a low hit rate, identifying only CPI-169 and the positive control, GRL0617, as inhibitors with good potency (IC50 < 10 lower case Greek μM). Analogues of both inhibitors were designed to develop structure-activity relationships; however, without a co-crystal structure of the CPI-169 series, we focused on GRL0617 as a starting point for structure-based drug design, obtaining several co-crystal structures to guide optimization. A series of novel 2-phenylthiophene-based non-covalent SARS-CoV-2 PLpro inhibitors were obtained, culminating in low nanomolar potency. The high potency and slow inhibitor off-rate were rationalized by newly identified ligand interactions with a 'BL2 groove' that is distal from the active site cysteine. Trapping of the conformationally flexible BL2 loop by these inhibitors blocks binding of viral and host protein substrates; however, until now it has not been demonstrated that this mechanism can induce potent and efficacious antiviral activity. In this study, we report that novel PLpro inhibitors have excellent antiviral efficacy and potency against infectious SARS-CoV-2 replication in cell cultures. Together, our data provide structural insights into the design of potent PLpro inhibitors and the first validation that non-covalent inhibitors of SARS-CoV-2 PLpro can block infection of human cells with low micromolar potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Protein production by auto-induction in high-density shaking cultures
Studier, F. W. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2005.01.016 · Cited by 5,931
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z.-L. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,515
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
Molecular replacement with MOLREP
Vagin, A., & Teplyakov, A. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042589 · Cited by 3,604
Coronavirus biology and replication: implications for SARS-CoV-2
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,197
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,330
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,597
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
Shin, D., Mukherjee, R., Grewe, D., Bojkova, D., Baek, K., Bhattacharya, A., Schulz, L., Widera, M., Mehdipour, A. R., Tascher, G., et al. (2020) · Nature · doi:10.1038/s41586-020-2601-5 · Cited by 1,177
Ma, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0356-z · Cited by 880
Báez-Santos, Y. M., St. John, S. E., & Mesecar, A. D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2014.12.015 · Cited by 854
Mechanisms and enzymes involved in SARS coronavirus genome expression
Thiel, V., Ivanov, K. A., Putics, Á., Hertzig, T., Schelle, B., Bayer, S., Weißbrich, B., Snijder, E. J., Rabenau, H., Doerr, H. W., et al. (2003) · Journal of General Virology · doi:10.1099/vir.0.19424-0 · Cited by 848
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Lei, J., Kusov, Y., & Hilgenfeld, R. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.001 · Cited by 727
Strong, M., Sawaya, M. R., Wang, S., Phillips, M., Cascio, D., & Eisenberg, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602606103 · Cited by 701
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
Chu, H., Chan, J. F.-W., Wang, Y., Yuen, T. T.-T., Chai, Y., Hou, Y., Shuai, H., Yang, D., Hu, B., Huang, X., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa410 · Cited by 667
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
Barretto, N., Jukneliene, D., Ratia, K., Chen, Z., Mesecar, A. D., & Baker, S. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15189-15198.2005 · Cited by 582
Self-citationA noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., Chaudhuri, R., Fu, W., Prabhakar, B. S., Johnson, M. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805240105 · Cited by 507
Self-citationHoffman, R. L., Kania, R. S., Brothers, M. A., Davies, J. F., Ferre, R. A., Gajiwala, K. S., He, M., Hogan, R. J., Kozminski, K., Li, L. Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01063 · Cited by 507
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
Klemm, T., Ebert, G., Calleja, D. J., Allison, C. C., Richardson, L. W., Bernardini, J. P., Lu, B. G., Kuchel, N. W., Grohmann, C., Shibata, Y., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106275 · Cited by 485
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
Osipiuk, J., Azizi, S.-A., Dvorkin, S., Endres, M., Jedrzejczak, R., Jones, K. A., Kang, S., Kathayat, R. S., Kim, Y., Lisnyak, V. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21060-3 · Cited by 462
Rut, W., Lv, Z., Zmudzinski, M., Patchett, S., Nayak, D., Snipas, S. J., El Oualid, F., Huang, T. T., Bekes, M., Drag, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.abd4596 · Cited by 459
Ratia, K., Saikatendu, K. S., Santarsiero, B. D., Barretto, N., Baker, S. C., Stevens, R. C., & Mesecar, A. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510851103 · Cited by 414
Self-citationSacco, M. D., Ma, C., Lagarias, P., Gao, A., Townsend, J. A., Meng, X., Dube, P., Zhang, X., Hu, Y., Kitamura, N., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe0751 · Cited by 385
Lindner, H. A., Fotouhi-Ardakani, N., Lytvyn, V., Lachance, P., Sulea, T., & Ménard, R. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15199-15208.2005 · Cited by 371
Frieman, M., Ratia, K., Johnston, R. E., Mesecar, A. D., & Baric, R. S. (2009) · Journal of Virology · doi:10.1128/jvi.02220-08 · Cited by 368
Self-citationFu, Z., Huang, B., Tang, J., Liu, S., Liu, M., Ye, Y., Liu, Z., Xiong, Y., Zhu, W., Cao, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20718-8 · Cited by 322
Kruse, R. L. (2020) · F1000Research · doi:10.12688/f1000research.22211.1 · Cited by 311
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306
Freitas, B. T., Durie, I. A., Murray, J., Longo, J. E., Miller, H. C., Crich, D., Hogan, R. J., Tripp, R. A., & Pegan, S. D. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00168 · Cited by 290
Drug–Target Kinetics in Drug Discovery
Tonge, P. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00185 · Cited by 287
Chen, X., Yang, X., Zheng, Y., Yang, Y., Xing, Y., & Chen, Z. (2014) · Protein & Cell · doi:10.1007/s13238-014-0026-3 · Cited by 272
Báez-Santos, Y. M., Barraza, S. J., Wilson, M. W., Agius, M. P., Mielech, A. M., Davis, N. M., Baker, S. C., Larsen, S. D., & Mesecar, A. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401712t · Cited by 255
Siklos, M., BenAissa, M., & Thatcher, G. R. J. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.08.001 · Cited by 249
Self-citationRatia, K., Kilianski, A., Baez-Santos, Y. M., Baker, S. C., & Mesecar, A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004113 · Cited by 224
Self-citationApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response
Wang, C., Zhang, M., Garcia, G., Tian, E., Cui, Q., Chen, X., Sun, G., Wang, J., Arumugaswami, V., & Shi, Y. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2020.12.018 · Cited by 223
Ubiquitin enzymes in the regulation of immune responses
Ebner, P., Versteeg, G. A., & Ikeda, F. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1325829 · Cited by 161
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., Beutler, N., Binder, J., Chen, E., Eng, H., et al. (2020) · doi:10.1101/2020.09.12.293498 · Cited by 154
Ghosh, A. K., Takayama, J., Rao, K. V., Ratia, K. M., Chaudhuri, R., Mulhearn, D. C., Lee, H., Nichols, D. B., Baliji, S., Baker, S. C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004489 · Cited by 151
Self-citationGhosh, A. K., Takayama, J., Aubin, Y., Ratia, K., Chaudhuri, R., Baez, Y., Sleeman, K., Coughlin, M., Nichols, D. B., Mulhearn, D. C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900611t · Cited by 129
Self-citationRole of Multiple Drug Resistance Protein 1 in Neutral but Not Acidic Glycosphingolipid Biosynthesis
Rosa, M. F. D., Sillence, D. J., Ackerley, C. A., & Lingwood, C. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305645200 · Cited by 114
Muley, L., Baum, B., Smolinski, M. P., Freindorf, M., Heine, A., Klebe, G., & Hangauer, D. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016416 · Cited by 97
Lafleur, K., Danzhi Huang, A., Zhou, T., Caflisch, A., & Nevado, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9009444 · Cited by 96
Potential COVID-19 papain-like protease PL pro inhibitors: repurposing FDA-approved drugs
Kouznetsova, V. L., Zhang, A., Tatineni, M., Miller, M. A., & Tsigelny, I. F. (2020) · PeerJ · doi:10.7717/peerj.9965 · Cited by 72
The papain-like protease of coronaviruses cleaves ULK1 to disrupt host autophagy
Mohamud, Y., Xue, Y. C., Liu, H., Ng, C. S., Bahreyni, A., Jan, E., & Luo, H. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.12.091 · Cited by 49
del Ser, T., Fernández‐Blázquez, M. A., Valentí, M., Zea‐Sevilla, M. A., Frades, B., Alfayate, E., Saiz-Aúz, L., Calero, O., López, F. J. G., Rábano, A., et al. (2021) · Gerontology · doi:10.1159/000513182 · Cited by 49
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2
Smith, E. W., Davis-Gardner, M. E., Garcia-Ordoñez, R. D., Nguyen, T.-T. H., Hull, M. V., Chen, E., Baillargeon, P., Scampavia, L. D., Strutzenberg, T. S., Griffin, P. R., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220963667 · Cited by 45
Lai, C., Li, H., Yu, W., Shah, S., Bommineni, G. R., Perrone, V., García–Díaz, M., Tonge, P. J., & Simmerling, C. L. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00284 · Cited by 42
Cited by
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
Gentile, F., Yaacoub, J. C., Gleave, J., Fernandez, M., Ton, A.-T., Ban, F., Stern, A., & Cherkasov, A. (2022) · Nature Protocols · doi:10.1038/s41596-021-00659-2 · Cited by 397
The IUPHAR/BPS Guide to PHARMACOLOGY in 2024
Harding, S. D., Armstrong, J. F., Faccenda, E., Southan, C., Alexander, S. P. H., Davenport, A. P., Spedding, M., & Davies, J. A. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad944 · Cited by 226
Language models for the prediction of SARS-CoV-2 inhibitors
Blanchard, A. E., Gounley, J., Bhowmik, D., Chandra Shekar, M., Lyngaas, I., Gao, S., Yin, J., Tsaris, A., Wang, F., & Glaser, J. (2022) · The International Journal of High Performance Computing Applications · doi:10.1177/10943420221121804 · Cited by 30
Metadata
- Authors
- Shen, Z., Ratia, K., Cooper, L., Kong, D., Lee, H., Kwon, Y., Li, Y., Alqarni, S., Huang, F., Dubrovskyi, O., Rong, L., Thatcher, G. R. J., & Xiong, R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-19
- Volume
- 65
- Issue
- 4
- Pages
- 2940-2955
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3207670255
- Cited by
- 224
- References
- 61
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.